Cyclosporiasis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Joseph Nasr, M.D.[2] Ammu Susheela, M.D. [3]

Cyclosporiasis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Cyclosporiasis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X-Ray
CT Scan
MRI
Ultrasound
Treatment
Medical Therapy
Primary Prevention
Case Studies
Case #1
Cyclosporiasis medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
slides
Images
American Roentgen Ray Society Images of Cyclosporiasis medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Cyclosporiasis medical therapy
on Cyclosporiasis medical therapy
Cyclosporiasis medical therapy in the news
Blogs on Cyclosporiasis medical therapy
Directions to Hospitals Treating Cyclosporiasis
Risk calculators and risk factors for Cyclosporiasis medical therapy

Overview

Cyclosporiasis is treated primarily with trimethoprim-sulfamethoxazole (TMP-SMX), which is the treatment of choice for symptomatic infection. In its July 14, 2026 Health Advisory, the Centers for Disease Control and Prevention (CDC) recommended treating confirmed cyclosporiasis in immunocompetent adults and children aged 2 months or older with 7–10 days of TMP-SMX and considering longer courses in patients with immunocompromising conditions.

Cyclosporiasis in an immunocompetent patient may eventually resolve without antimicrobial therapy, but untreated illness can persist for weeks or longer and may follow a remitting-relapsing course. Patients with HIV infection, solid-organ transplantation, or another substantial immunocompromising condition are at increased risk of severe, prolonged, or recurrent disease and may require longer treatment, specialist-directed dosing, and, in selected recurrent cases, secondary prophylaxis.

Supportive therapy for cyclosporiasis includes oral or intravenous fluid replacement, correction of clinically important electrolyte abnormalities, continued age-appropriate nutrition, and nutritional support when prolonged diarrhea causes weight loss, malabsorption, or malnutrition.

Medical Therapy

Core treatment principles

Cyclosporiasis should be treated with pathogen-directed therapy after confirmation whenever feasible because persistent watery diarrhea has a broad infectious and noninfectious differential diagnosis. The 2026 CDC Health Advisory specifically recommends treatment of confirmed cases; patients with severe immunocompromise may require individualized empiric management while testing is pending.

Clinical setting	Recommended approach	Key qualification
Confirmed symptomatic cyclosporiasis	Treat with oral TMP-SMX	TMP-SMX is the treatment of choice.
Mild disease in an immunocompetent patient who cannot receive TMP-SMX	Observation plus supportive care may be considered	Most immunocompetent patients eventually recover, but illness may be prolonged or relapse.
Severe, prolonged, recurrent, or immunocompromised-host disease	Treat with TMP-SMX and individualize duration; obtain infectious diseases guidance when the response is inadequate or recurrence risk is high	Current CDC guidance supports a longer course but does not specify a universal intensified regimen.
Persistent watery diarrhea without a confirmed pathogen	Continue diagnostic evaluation rather than routinely giving nonspecific empiric antimicrobial therapy	Protozoal diarrhea is best managed with pathogen-specific therapy; an exception may be appropriate in a severely immunocompromised patient.

Trimethoprim-sulfamethoxazole

Cyclosporiasis is most reliably treated with the combination of trimethoprim and sulfamethoxazole.

Mechanism of action

In cyclosporiasis, TMP-SMX is understood to inhibit sequential steps in folate metabolism: sulfamethoxazole inhibits dihydropteroate synthase, whereas trimethoprim inhibits dihydrofolate reductase, thereby impairing tetrahydrofolate-dependent nucleic-acid synthesis. The U.S. prescribing information describes these targets for susceptible bacteria; the exact antiparasitic pharmacodynamics in Cyclospora cayetanensis are less completely characterized.

Regulatory status

In cyclosporiasis, TMP-SMX use is recommended by the CDC and the Infectious Diseases Society of America but is not listed as an FDA-approved indication in the current U.S. oral TMP-SMX prescribing information. Its use for cyclosporiasis is therefore guideline-supported and off-label.

Recommended doses and duration

Cyclosporiasis dosing should be expressed using both the trimethoprim and sulfamethoxazole components, with pediatric calculations based on total daily milligrams per kilogram divided into two doses.

Population	Preferred regimen	Duration	Clinical notes
Immunocompetent adults	TMP 160 mg/SMX 800 mg orally twice daily	7–10 days	One double-strength tablet per dose. This is the standard CDC regimen.
Children aged 2 months to 18 years	TMP 8–10 mg/kg/day plus SMX 40–50 mg/kg/day orally in 2 divided doses	7–10 days	Equivalent to TMP 4–5 mg/kg plus SMX 20–25 mg/kg per dose every 12 hours. Verify the formulation concentration when using an oral suspension.
Infants aged younger than 2 months	No standard TMP-SMX regimen	—	TMP-SMX is contraindicated in current U.S. product labeling because of the risk of bilirubin displacement and kernicterus. Obtain pediatric infectious diseases guidance.
Patients with HIV or another immunocompromising condition	Begin with the age-appropriate CDC regimen	At least 7–10 days; consider a longer course according to clinical response	Current CDC guidance does not define a single universal higher-dose regimen. Severe, persistent, or recurrent disease should be individualized.

Administration and oral formulations

Cyclosporiasis is ordinarily treated orally; one double-strength tablet contains TMP 160 mg/SMX 800 mg, and one single-strength tablet contains TMP 80 mg/SMX 400 mg. Oral suspensions are available in different marketed presentations, and the concentration must be checked before calculating a pediatric volume. Adequate fluid intake and urinary output should be maintained during TMP-SMX therapy to reduce the risk of crystalluria.

Cyclosporiasis does not have a validated or CDC-specified intravenous TMP-SMX regimen. If oral administration is impossible or clinically important malabsorption is suspected, infectious diseases and pharmacy consultation is appropriate rather than automatically substituting an intravenous regimen approved for a different indication.

Renal dose adjustment

Cyclosporiasis treatment in patients with renal impairment requires adjustment based on the current product label, although these renal recommendations were not specifically validated for the off-label Cyclospora indication.

Creatinine clearance	Current oral-label recommendation	Application to cyclosporiasis
Greater than 30 mL/min	Use the usual standard regimen	Use the age-appropriate CDC regimen unless another patient-specific reason requires modification.
15–30 mL/min	Use one-half of the usual regimen	Determine the practical dose and interval with pharmacy or infectious diseases input, especially in severe or immunocompromised-host disease.
Less than 15 mL/min	Use is not recommended	Select an individualized approach with infectious diseases and renal-pharmacy guidance; no Cyclospora-specific dialysis regimen is established.

Treatment in special populations

Cyclosporiasis in a special population requires separation of current CDC recommendations from older limited studies and from guidance written for other coccidian infections.

People with HIV

Cyclosporiasis in people with HIV should be treated with TMP-SMX, with a longer course considered when disease is severe, prolonged, recurrent, or associated with advanced immunosuppression. Antiretroviral therapy should be initiated or optimized, and persistent diarrhea should prompt evaluation for additional opportunistic enteric infections, poor virologic control, severe malabsorption, biliary disease, reinfection, or continued exposure.

Historical Cyclospora studies in Haiti provide options for specialist-directed care but should not be mistaken for a current NIH Cyclospora treatment table. The current NIH opportunistic-infection guideline contains a chapter for cystoisosporiasis, not a separate Cyclospora regimen; pyrimethamine, leucovorin, and cystoisosporiasis-specific prophylaxis schedules should not be copied into a cyclosporiasis chapter.

Evidence source	Studied Cyclospora regimen	Interpretation
Pape et al., 1994	TMP 160 mg/SMX 800 mg orally four times daily for 10 days; patients who responded received one double-strength tablet three times weekly as secondary prophylaxis	Prospective cohort in adults with HIV; showed response but a high recurrence risk. This is historical evidence, not a universal current CDC dose.
Verdier et al., 2000	TMP 160 mg/SMX 800 mg orally twice daily for 7 days; responders received one tablet three times weekly for 10 weeks	Small randomized trial enrolling 42 patients with HIV, including 20 with Cyclospora and 22 with Cystoisospora; TMP-SMX was more effective than ciprofloxacin, but organism-specific outcomes were not fully separated.

Secondary prophylaxis after cyclosporiasis is not routinely required for every person with HIV. It may be considered after recurrent disease or in advanced immunosuppression when immune recovery is not expected promptly, using an individualized plan developed with an HIV or infectious diseases specialist. The optimal regimen and stopping criteria have not been established in a current Cyclospora-specific U.S. guideline.

Solid-organ transplant recipients

Cyclosporiasis in solid-organ transplant recipients should be managed with transplant infectious diseases input because evidence is limited, drug interactions are clinically important, and the optimal duration of treatment and secondary prophylaxis is uncertain. The 2019 American Society of Transplantation Infectious Diseases Community of Practice guideline remains the most recent transplant-specific Cyclospora guidance identified.

AST recommendation	Regimen or action	Strength and certainty	Current interpretation
Preferred treatment	TMP 160 mg/SMX 800 mg orally four times daily for 10 days, followed by TMP 160 mg/SMX 800 mg orally three times weekly as secondary prophylaxis	Strong recommendation; low-quality evidence	Do not automatically apply this intensified regimen to immunocompetent patients. Confirm renal function, potassium, blood counts, and drug interactions.
Alternative for sulfonamide intolerance	Ciprofloxacin 500 mg orally twice daily for 7 days, followed by 500 mg orally three times weekly as secondary prophylaxis	Weak recommendation; low-quality evidence	Ciprofloxacin is less reliable than TMP-SMX and is not an equivalent first-line agent.
Adjustment of immunosuppression	Reduce immunosuppression when clinically feasible	Strong recommendation; very low-quality evidence	Balance infection control against rejection risk with the transplant team.

Cyclosporiasis treatment in a transplant recipient must account for TMP-SMX-associated hyperkalemia, nephrotoxicity, and bone-marrow suppression, as well as additive renal toxicity with calcineurin inhibitors. A 2025 heart-transplant case was successfully managed with TMP 160 mg/SMX 800 mg twice daily for 14 days followed by time-limited secondary prophylaxis, illustrating that contemporary practice may individualize the 2019 guideline regimen rather than treat it as a high-certainty standard.

Pregnancy

Cyclosporiasis during pregnancy requires individualized maternal-fetal risk assessment. CDC clinical guidance states that TMP-SMX should be used only when the potential benefit justifies the potential fetal risk and should be avoided near term because of the potential for neonatal hyperbilirubinemia and kernicterus.

Current U.S. labeling is product-specific and not uniform. The 2025 FDA oral double-strength tablet label cited here lists pregnancy as a contraindication and retains an older pregnancy-letter category, whereas other currently marketed generic labels describe embryo-fetal toxicity under warnings and advise use only when benefit justifies risk. The exact dispensed product label should therefore be checked. Trimethoprim interferes with folate metabolism, but no Cyclospora-specific folic-acid supplementation dose has been established. Obstetric and infectious diseases consultation is appropriate when treatment is clinically necessary.

Lactation

Cyclosporiasis during lactation also requires reconciliation of CDC clinical advice with product-specific labeling. CDC and LactMed state that TMP-SMX is generally compatible with breastfeeding a healthy, full-term infant after the newborn period, but it should generally be avoided when the infant is premature, jaundiced, ill, stressed, or known or suspected to have glucose-6-phosphate dehydrogenase deficiency.

The 2025 FDA oral double-strength tablet label cited here lists nursing mothers under contraindications, whereas other current oral generic labels advise caution; the current intravenous label advises avoiding breastfeeding during treatment. The exact formulation and product-specific labeling should be reviewed before prescribing.

Older adults, hepatic impairment, folate deficiency, and G6PD deficiency

Cyclosporiasis treatment with TMP-SMX carries a higher risk of severe adverse reactions in older adults, particularly with renal or hepatic impairment, possible folate deficiency, or interacting medications. Current labeling advises avoiding or using particular caution in marked hepatic damage, renal impairment, folate-deficiency states, porphyria, thyroid dysfunction, and G6PD deficiency; hemolysis in G6PD deficiency may be dose-related.

Sulfonamide allergy, TMP-SMX intolerance, and alternative therapy

Cyclosporiasis has no alternative antimicrobial regimen with efficacy comparable to TMP-SMX. The reported reaction should be characterized because isolated gastrointestinal intolerance or a remote mild rash is clinically different from anaphylaxis or a severe delayed immune-mediated reaction.

TMP-SMX desensitization

Cyclosporiasis requiring antimicrobial therapy may be managed with TMP-SMX desensitization only in a selected patient who has been evaluated by an allergy specialist and does not have a life-threatening allergy. Rechallenge or desensitization should not be attempted after Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms, acute generalized exanthematous pustulosis, severe drug-associated hepatitis, nephritis, pneumonitis, hemophagocytic lymphohistiocytosis, or another life-threatening immune-mediated reaction.

Alternative approaches

Cyclosporiasis alternatives should be described as limited-evidence options, not as equivalent substitutes for TMP-SMX.

Option	Regimen	Evidence and clinical role
Observation and supportive care	No antimicrobial regimen	Reasonable for selected immunocompetent patients with mild disease who cannot receive TMP-SMX, provided hydration and follow-up are adequate.
Ciprofloxacin	500 mg orally twice daily for 7 days in the small adult HIV trial	Demonstrated modest activity but was less effective than TMP-SMX. CDC notes substantial anecdotal experience suggesting ineffectiveness in many immunocompetent patients; it should not be presented as an equivalent alternative.
Nitazoxanide	No established Cyclospora-specific standard regimen	Case reports and uncontrolled observations suggest possible activity, including after ciprofloxacin failure, but evidence is insufficient for a guideline-equivalent regimen. Nitazoxanide is not FDA-approved for cyclosporiasis.

Agents without established efficacy

Cyclosporiasis should not routinely be treated with agents that the CDC identifies as ineffective on the basis of anecdotal or unpublished data:

• Albendazole
• Azithromycin
• Diloxanide furoate
• Doxycycline
• Metronidazole
• Nalidixic acid
• Quinacrine
• Tetracycline
• Tinidazole
• Trimethoprim monotherapy

Pyrimethamine plus leucovorin is a recognized alternative in certain cystoisosporiasis guidelines, but it is not a current CDC-recommended regimen for cyclosporiasis and should not be imported into this chapter.

Supportive care

Cyclosporiasis supportive care is essential when diarrhea causes dehydration, electrolyte loss, weight loss, or malnutrition and should not be replaced by an antimicrobial prescription alone.

Clinical problem	Supportive management	Current guidance
Mild-to-moderate dehydration	Reduced-osmolarity oral rehydration solution	First-line rehydration for infants, children, and adults; replace ongoing stool losses.
Moderate dehydration with inability or refusal to drink	Consider nasogastric oral rehydration solution	May be used when mental status is normal and aspiration risk is acceptable.
Severe dehydration, shock, altered mental status, failed oral rehydration, or ileus	Intravenous isotonic fluid such as lactated Ringer solution or normal saline	Continue until perfusion, pulse, mental status, and oral tolerance improve.
Prolonged illness, weight loss, or malabsorption	Assess nutritional status; continue or resume an age-appropriate diet; provide protein-calorie and micronutrient support when deficient	Breastfeeding should continue during diarrheal illness when otherwise appropriate.
Symptomatic diarrhea	Consider an antimotility agent only in an adequately hydrated, immunocompetent adult with acute watery diarrhea	Do not give antimotility drugs to patients younger than 18 years; avoid at any age when fever, inflammatory diarrhea, colitis, or toxic megacolon is suspected.
Vomiting that prevents oral rehydration	Consider an antiemetic when clinically appropriate	Ondansetron may facilitate oral rehydration in children older than 4 years and adolescents with acute gastroenteritis.
Child aged 6 months to 5 years in a high-zinc-deficiency setting or with malnutrition	Consider oral zinc supplementation	IDSA supports zinc in this defined population; it is not a Cyclospora-specific antiparasitic treatment.

Hospitalization for cyclosporiasis may be required for severe dehydration, inability to maintain oral intake, severe electrolyte disturbance, hemodynamic instability, severe malabsorption or malnutrition, significant acute kidney injury, serious medication toxicity, or decompensation of a major comorbidity.

Clinical response, treatment failure, relapse, and follow-up

Cyclosporiasis generally begins to improve within several days of effective TMP-SMX therapy. Failure to improve, deterioration, or recurrence after an initial response should prompt reassessment rather than automatic repetition of the same regimen.

Reassess for:

• Incorrect diagnosis or a false-positive multiplex molecular result
• Inadequate adherence, incorrect dose, premature discontinuation, or an inappropriate renal adjustment
• Vomiting or clinically important malabsorption
• Reinfection or continued exposure to contaminated food or water
• Another enteric pathogen, including an opportunistic infection in an immunocompromised patient
• Antibiotic-associated diarrhea, including Clostridioides difficile infection
• Unrecognized or worsening immunosuppression
• Poor HIV virologic control or inadequate immune recovery
• Biliary disease, severe malnutrition, or another complication
• A noninfectious cause of persistent diarrhea, including inflammatory bowel disease, celiac disease, or postinfectious irritable bowel syndrome

Cyclosporiasis with persistent or recurrent symptoms may require repeat Cyclospora-specific stool testing, often using specimens collected on different days because oocyst shedding can be intermittent and low-level. Routine test-of-cure testing is generally unnecessary after complete clinical resolution when the result would not change management.

Cyclosporiasis that persists despite a verified standard course should be discussed with infectious diseases. A longer course, an intensified regimen, or secondary prophylaxis may be appropriate in selected immunocompromised patients, but no single escalation schedule is established for all patients.

Medication safety, contraindications, and monitoring

Cyclosporiasis treatment with TMP-SMX requires attention to product-specific contraindications, renal function, electrolyte and hematologic toxicity, severe immune-mediated reactions, and drug interactions.

Contraindications and major precautions

Cyclosporiasis should not be treated with TMP-SMX when a contraindication in the exact dispensed product label applies.

Label issue	Current labeling	Clinical implication
Hypersensitivity	Known hypersensitivity to trimethoprim or sulfonamides is contraindicated	Clarify the phenotype and severity; do not rechallenge after a life-threatening immediate or delayed reaction.
Prior hematologic reaction	Some current labels contraindicate prior TMP- or sulfonamide-induced immune thrombocytopenia and documented megaloblastic anemia due to folate deficiency	Review previous drug-associated cytopenias and folate status.
Age younger than 2 months	Contraindicated	Obtain pediatric infectious diseases guidance; do not extrapolate the routine pediatric regimen.
Marked hepatic damage	Contraindicated in current oral labels	Select an individualized alternative strategy.
Severe renal insufficiency when renal function cannot be monitored	Contraindicated	TMP-SMX is not recommended below a creatinine clearance of 15 mL/min in the cited oral label.
Dofetilide	Concomitant use is contraindicated in some current generic oral labels	Verify the exact label and medication list; avoid the combination when applicable.
Pregnancy and lactation	Product-specific U.S. labels differ; the cited 2025 FDA oral label lists pregnancy and nursing as contraindications, whereas other current oral labels use warnings and precautions	Reconcile the exact product label with CDC clinical guidance and obtain specialist input.

Adverse reactions

Cyclosporiasis treatment with TMP-SMX most commonly causes gastrointestinal symptoms and allergic skin reactions, but rare serious or fatal reactions are described in current labeling.

Category	Important reactions
Common	Nausea, vomiting, anorexia, rash, and urticaria
Severe cutaneous and immune-mediated	Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS, acute generalized exanthematous pustulosis, acute febrile neutrophilic dermatosis, anaphylaxis, circulatory shock, and hemophagocytic lymphohistiocytosis
Hematologic	Immune thrombocytopenia, leukopenia, neutropenia, agranulocytosis, aplastic anemia, megaloblastic anemia, methemoglobinemia, and hemolysis in G6PD deficiency
Renal and electrolyte	Increased serum creatinine, interstitial nephritis, acute kidney injury, crystalluria, hyperkalemia, and hyponatremia
Hepatic and gastrointestinal	Hepatitis, cholestatic jaundice, hepatic necrosis, pancreatitis, and C. difficile-associated diarrhea
Pulmonary	Hypersensitivity pneumonitis, acute eosinophilic pneumonia, interstitial lung disease, and acute or delayed respiratory failure
Other	Hypoglycemia, aseptic meningitis, photosensitivity, QT prolongation with ventricular arrhythmia, and rhabdomyolysis

TMP-SMX should be stopped and urgent evaluation obtained at the first appearance of a concerning rash or another possible serious reaction, including fever, pharyngitis, arthralgia, cough, chest pain, dyspnea, pallor, purpura, jaundice, severe hypotension, or unexplained systemic inflammation.

Monitoring

Cyclosporiasis treatment monitoring should be individualized according to dose, duration, age, renal and hepatic function, comorbidity, volume status, and interacting medications.

Before treatment, consider:

• Allergy and severe cutaneous adverse-reaction history
• Complete medication reconciliation
• Baseline serum creatinine and estimated creatinine clearance
• Baseline potassium and sodium in patients at increased risk
• Baseline complete blood count when treatment will be prolonged or high-dose, or when cytopenia risk is increased
• Hepatic function in patients with known or suspected liver disease
• Pregnancy and lactation status when relevant
• Known or suspected G6PD deficiency
• Folate-deficiency risk, including malnutrition, malabsorption, advanced age, chronic alcohol use, kidney failure, or anticonvulsant therapy

During treatment, monitor renal function, electrolytes, and complete blood count more closely in patients receiving a prolonged or intensified course and in those with renal impairment, older age, transplant medications, potassium-raising drugs, or other major risk factors. Current labeling advises periodic complete blood counts, clinical chemistry testing, urinalysis, and renal-function tests, particularly in patients with impaired renal function.

Clinically important drug interactions

Cyclosporiasis treatment with TMP-SMX requires review for interactions mediated through CYP2C8, CYP2C9, renal transporters, additive hyperkalemia, nephrotoxicity, and bone-marrow toxicity.

Concomitant drug or class	Main concern	Label-based action
Dofetilide	Increased dofetilide exposure and proarrhythmia	Contraindicated in some current oral labels; verify the exact product label.
Warfarin	Increased anticoagulant effect	Monitor prothrombin time and INR and adjust anticoagulation as needed.
Phenytoin	Reduced metabolism and phenytoin toxicity	Monitor clinical status and serum phenytoin concentration.
Methotrexate	Increased free methotrexate exposure and additive marrow toxicity	Avoid concurrent use when possible.
Cyclosporine	Marked but reversible nephrotoxicity, particularly in renal transplant recipients	Avoid concurrent use when possible or monitor very closely with the transplant team.
Digoxin	Increased digoxin concentration, especially in older adults	Monitor serum digoxin concentration and toxicity.
ACE inhibitors, angiotensin receptor blockers, potassium-sparing diuretics, or potassium supplements	Hyperkalemia	Avoid or monitor potassium and renal function closely according to clinical necessity.
Thiazide diuretics	Increased thrombocytopenia with purpura in older adults	Monitor for bleeding and cytopenia.
Sulfonylureas and other susceptible oral hypoglycemic agents	Potentiated hypoglycemia	Monitor glucose more frequently.
Zidovudine	Additive hematologic toxicity	Monitor complete blood count.
Pyrimethamine	Increased risk of megaloblastic anemia	Avoid the combination, particularly with pyrimethamine doses greater than 25 mg/week.

Clinical considerations and common pitfalls

Cyclosporiasis management is commonly compromised by importing recommendations from cystoisosporiasis or by presenting low-quality special-population evidence as a universal standard.

• Do not apply NIH cystoisosporiasis doses, pyrimethamine regimens, evidence grades, or prophylaxis stopping criteria to cyclosporiasis.
• Do not describe the CDC-recommended Cyclospora regimen as FDA-approved; it is guideline-supported off-label use.
• Do not apply historical high-dose HIV regimens or the low-certainty AST transplant regimen to immunocompetent adults.
• Do not treat ciprofloxacin as equivalent to TMP-SMX.
• Do not present nitazoxanide as an established first-line alternative or assign it a standard Cyclospora dose unsupported by guidelines.
• Do not assume that intravenous TMP-SMX has a validated Cyclospora regimen.
• Do not use obsolete FDA pregnancy-letter categories as current clinical grading.
• Do not overlook product-specific differences in pregnancy, lactation, dofetilide, and other labeling.
• Do not omit renal dose adjustment, hydration, electrolyte monitoring, or interaction review.
• Do not perform TMP-SMX rechallenge or desensitization after a life-threatening immediate reaction or severe delayed immune-mediated reaction.
• Do not continue secondary prophylaxis indefinitely without reassessing immune recovery, recurrence risk, drug toxicity, and the limited evidence supporting prophylaxis.
• Do not use routine test-of-cure testing after complete clinical resolution when the result would not alter management.